A mouse model of Clostridium difficile-associated disease.
暂无分享,去创建一个
Jeffrey D Goldsmith | D. Gerding | C. Kelly | Xinhua Chen | Dale N Gerding | Xinhua Chen | Kianoosh Katchar | Nanda Nanthakumar | Adam Cheknis | Ciarán P Kelly | J. Goldsmith | K. Katchar | N. Nanthakumar | Adam K Cheknis
[1] T. Monath,et al. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters , 1995, Infection and immunity.
[2] J. Silva,et al. Mucosal damage mediated by clostridial toxin in experimental clindamycin-associated colitis. , 1980, Gut.
[3] J. Ketley,et al. Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon. , 1986, Gut.
[4] S. Schnitt,et al. Massive mural edema in severe pseudomembranous colitis. , 1983, Archives of pathology & laboratory medicine.
[5] C. Pothoulakis,et al. Direct evidence of mast cell involvement in Clostridium difficile toxin A-induced enteritis in mice. , 1998, Gastroenterology.
[6] C. Pothoulakis,et al. Comparative Efficacies of Rifaximin and Vancomycin for Treatment of Clostridium difficile-Associated Diarrhea and Prevention of Disease Recurrence in Hamsters , 2008, Antimicrobial Agents and Chemotherapy.
[7] J. Gerberding,et al. Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005. , 2005, MMWR. Morbidity and mortality weekly report.
[8] J. Silva,et al. Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. , 1979, Reviews of infectious diseases.
[9] K. Horton,et al. Pseudomembranous colitis: spectrum of imaging findings with clinical and pathologic correlation. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.
[10] E. Jennische,et al. Enterotoxins from Clostridium difficile; diarrhoeogenic potency and morphological effects in the rat intestine. , 1990, Gut.
[11] C. Pothoulakis,et al. Rifalazil Treats and Prevents Relapse of Clostridium difficile-Associated Diarrhea in Hamsters , 2004, Antimicrobial Agents and Chemotherapy.
[12] J. Silva,et al. Clindamycin-induced enterocolitis in hamsters. , 1978, The Journal of infectious diseases.
[13] C. Pothoulakis,et al. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. , 1994, The Journal of clinical investigation.
[14] K. Wilson,et al. Gnotobiotic models for study of the microbial ecology of Clostridium difficile and Escherichia coli. , 1986, The Journal of infectious diseases.
[15] D. Gerding,et al. Infection of hamsters with epidemiologically important strains of Clostridium difficile. , 2001, The Journal of infectious diseases.
[16] L. Peterson,et al. Fatal Pseudomembranous Colitis Associated with a Variant Clostridium difficile Strain Not Detected by Toxin A Immunoassay , 2001, Annals of Internal Medicine.
[17] K. Wilson,et al. Suppression of Clostridium difficile by Normal Hamster Cecal Flora and Prevention of Antibiotic-Associated Cecitis , 1981, Infection and immunity.
[18] J. Ballard,et al. Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication , 2006, Proceedings of the National Academy of Sciences.
[19] C. Kelly,et al. Update on Clostridium difficile associated disease , 2007, Current opinion in gastroenterology.
[20] Robert B. Mandell,et al. Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile-Induced Mortality in Hamsters , 2006, Infection and Immunity.
[21] C. Donskey,et al. Effect of Antibiotic Treatment on Growth of and Toxin Production by Clostridium difficile in the Cecal Contents of Mice , 2005, Antimicrobial Agents and Chemotherapy.
[22] N. Glaichenhaus,et al. Priming by Microbial Antigens from the Intestinal Flora Determines the Ability of CD4+ T Cells to Rapidly Secrete IL-4 in BALB/c Mice Infected with Leishmania major1 , 2000, The Journal of Immunology.
[23] T. Jodlowski,et al. Emerging Therapies in the Treatment of Clostridium difficile–Associated Disease , 2006, The Annals of pharmacotherapy.
[24] J. Bartlett,et al. Clostridium difficile in gnotobiotic mice , 1980, Infection and immunity.
[25] L. Mcfarland. Alternative treatments for Clostridium difficile disease: what really works? , 2005, Journal of medical microbiology.
[26] A. Limaye,et al. Pseudomembranous Colitis Caused by a Toxin A− B+ Strain of Clostridium difficile , 2000, Journal of Clinical Microbiology.
[27] C. Pothoulakis,et al. Purification and properties of Clostridium difficile cytotoxin B. , 1986, The Journal of biological chemistry.
[28] Kunitomo Watanabe,et al. Identification of Toxin A-Negative, Toxin B-Positive Clostridium difficile by PCR , 1998, Journal of Clinical Microbiology.
[29] C. Kelly,et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. , 2000, The New England journal of medicine.
[30] C. Pothoulakis,et al. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins , 1996, Antimicrobial agents and chemotherapy.
[31] K. Saum,et al. Effects of Clostridium difficile toxins given intragastrically to animals , 1985, Infection and immunity.
[32] C. Kelly,et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea , 2001, The Lancet.
[33] C. Pothoulakis,et al. IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. , 1997, The American journal of physiology.
[34] K. Sunakawa,et al. Experimental models of Clostridium difficile enterocolitis in gnotobiotic mice. , 1985, Progress in clinical and biological research.
[35] J. Kink,et al. Antibodies to Recombinant Clostridium difficile Toxins A and B Are an Effective Treatment and Prevent Relapse of C. difficile-Associated Disease in a Hamster Model of Infection , 1998, Infection and Immunity.
[36] F. Knoop. Clindamycin-associated enterocolitis in guinea pigs: evidence for a bacterial toxin , 1979, Infection and immunity.
[37] D. Bobak,et al. Roles of intracellular calcium and NF-kappa B in the Clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. , 1999, Journal of immunology.
[38] G. Corthier,et al. Interrelationships between digestive proteolytic activities and production and quantitation of toxins in pseudomembranous colitis induced by Clostridium difficile in gnotobiotic mice , 1989, Infection and immunity.
[39] C. Kelly,et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[40] T. Monath,et al. Serum Antitoxin Antibodies Mediate Systemic and Mucosal Protection from Clostridium difficileDisease in Hamsters , 1999, Infection and Immunity.
[41] W. J. Johnson,et al. Pseudomembranous colitis in Clostridium difficile-monoassociated rats , 1983, Infection and immunity.